7.205USD+1.62%Mkt Cap: 446.47M USDP/E: —Last update: 2026-05-26
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap446.47M USD
Enterprise Value327.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-51.04M USD
Revenue/Share—
Last Price7.205 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.34
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.23
EPS (TTM)-1.35
EPS (Forward)-1.31
52W Range
3.23049% of range11.41
52W High11.41 USD
52W Low3.230 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.82%
ROA-43.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.65M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.17%
Net Debt-104.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio20.34
Quick Ratio19.74
Book Value/Sh3.144 USD
Cash/Share1.693 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)26.20 USD
Target Range8.000 USD – 49.00 USD
# Analysts10
Ownership
Shares Out.61.18M
Float59.14M
Insiders3.50%
Institutions21.93%
Short Interest
Short Ratio1.6d
Short % Float7.47%
Short % Out.7.34%
Shares Short4.53M
Short (prev mo.)3.23M
Technical
SMA 506.223 (+15.8%)
SMA 2006.654 (+8.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)2.57M
Avg Vol (10d)843.72K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—